Home

Flagship Ventures Fund IV-Rx, L.P.

CIK 1590973 · last filed 2022-03-18

Flagship Ventures Fund IV-Rx, L.P. is a corporate insider who has filed 8 SEC Form 4 insider transactions across 5 companies since 2016. The most recent filing shows the insider bought $72.4M of AXLA on Mar 18, 2022. Across all open-market trades the lifetime net is −$77.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.10B across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.10B

Companies

5

Total Filings

8

Lifetime Open-Market Net

-$77.84M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Axcella Health Inc. (AXLA) Delisted 10%+ Owner 2,035,830 $0.40 $816.2K $172.42M 2 2022-03-18
EVLO 10%+ Owner 795,950 $0.00 $80 $33.60M 2 2021-02-04
MRNA 10%+ Owner 21,986,399 $49.91 $1.10B -$313.86M 2 2020-05-26
Rubius Therapeutics, Inc. (RUBY) Delisted 10%+ Owner 5,789,414 $0.08 $480.5K $0 1 2018-07-23
SYRS 10%+ Owner 838,664 $0.00 $335 $30.00M 1 2016-07-07

Recent Filings

8 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2022-03-18 Axcella Health Inc. (AXLA) Delisted Buy (P) +37,916,226 $72.42M EDGAR
2021-02-04 EVLO Buy (P) +1,040,000 $15.60M EDGAR
2020-05-26 MRNA Sell (S) −4,000,000 -$272.88M EDGAR
2019-12-11 MRNA Mixed −48,357,875 -$40.98M EDGAR
2019-05-15 Axcella Health Inc. (AXLA) Delisted Mixed +60,339,740 $100.00M EDGAR
2018-07-23 Rubius Therapeutics, Inc. (RUBY) Delisted Conv (C) +299,668,734 $0 EDGAR
2018-05-15 EVLO Mixed +59,613,572 $18.00M EDGAR
2016-07-07 SYRS Mixed +27,559,944 $30.00M EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.